Interleukin inhibitors and the associated risk of candidiasis

S Khan, H Bilal, MN Khan, W Fang, W Chang… - Frontiers in …, 2024 - frontiersin.org
Interleukins (ILs) are vital in regulating the immune system, enabling to combat fungal
diseases like candidiasis effectively. Their inhibition may cause enhanced susceptibility to …

Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM

OA Cornely, R Sprute, M Bassetti… - The Lancet Infectious …, 2025 - thelancet.com
Candida species are the predominant cause of fungal infections in patients treated in
hospital, contributing substantially to morbidity and mortality. Candidaemia and other forms …

[HTML][HTML] The Impact of Oral Microbiome Dysbiosis on the Aetiology, Pathogenesis, and Development of Oral Cancer

J Talapko, S Erić, T Meštrović, MM Stipetić, M Juzbašić… - Cancers, 2024 - mdpi.com
Simple Summary The problems associated with oral squamous cell carcinoma (OSCC) are
becoming increasingly apparent. Namely, cancer of the oral cavity is the most common …

Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis

J MacAlpine, MS Lionakis - Cell Host & Microbe, 2024 - cell.com
Candida spp. are members of the human mucosal microbiota that can cause opportunistic
diseases ranging from superficial infections to life-threatening invasive candidiasis. In …

Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations

A Kadhi, E Eid, MJ Massaad, I El-Rassy… - Frontiers in …, 2025 - frontiersin.org
Introduction Psoriasis and chronic mucocutaneous candidiasis (CMC), although distinct in
their clinical manifestations, often coexist within specific patient cohorts. Despite this …

Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis …

S Schwartzman, L Puig, AD Cohen… - Expert Opinion on …, 2024 - Taylor & Francis
Background This safety analysis investigates treatment-emergent mucosal/cutaneous
Candida infections in patients treated with ixekizumab (IXE), an anti-interleukin-17A …

Infection and infestation-related adverse events of biologics in psoriasis: insights from the food and drug administration adverse event reporting system (FAERS)

R Fang, Y Zhou, L Han, W Chen, Y Sun… - Expert Opinion on Drug …, 2024 - Taylor & Francis
Objective The study aims to thoroughly assess the adverse events related to infections and
infestations associated with biological agents used for psoriasis using the US Food and …

The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience-IL PSO (Italian …

M Megna, D Orsini, C Assorgi, A Balato… - Clinical and …, 2024 - academic.oup.com
Anti-interleukin (IL) 17 use has been associated with a higher risk of candidiasis, as this
cytokine is involved in maintaining mucosal barriers and orchestrating immune responses to …

Cryptococcosis Recent Perspectives

H Kushima, H Ishii - Medical Mycology Journal, 2025 - jstage.jst.go.jp
Approximately one million new cases of cryptococcosis develop each year worldwide,
resulting in approximately 600,000 deaths. Most cases occurred in HIV patients from African …

[PDF][PDF] Sex-based Disparities in Immune Response to Oral Candidiasis: A Wistar Rat Model Study.

E Sulistyani, IE Triwahyuni, Z Hamzah… - Malaysian Journal of …, 2024 - medic.upm.edu.my
Introduction: The minimal use of female animals for research can be the reason why many
therapies and treatments for women fail. Aims: This study aims to assess the impact of sex …